Our technology is based on the discovery that many aggressive forms of cancer cells over-express certain unique amino acid transporters on their cell surfaces for the intake of nutrients to support rapid tumor growth and proliferation. Exploiting this biology, Quadriga is developing novel targeted molecules against cancer cells that over-express these transporters. Our mission is to develop safer and more effective treatments for patients with cancer.
To date, we have demonstrated that our proprietary compounds are effective in inhibiting tumor growth in a dose dependent manner in human solid-tumor xenograft models. Moreover, our lead compound has demonstrated robust tumor regression. Based on these results, the company is advancing its lead compound into preclinical toxicology studies in an effort to file an Investigational New Drug (IND) with FDA for human clinical trials.